Skip to main content

Table 2 First-line chemotherapy for patients with UGC with SMIHigh and SMILow

From: Impact of skeletal muscle mass in patients with unresectable gastric cancer who received palliative first-line chemotherapy based on 5-fluorouracil

 

SMIHigh (n = 41)

SMILow (n = 42)

P value

Monotherapy

  

0.144

 S-1

4 (9.8)

9 (21.4)

 

Combined chemotherapy

37 (90.2)

33 (78.6)

 

 S-1 + cisplatin

6

13

 

 Combined S-1 + paclitaxel + intraperitoneally infused paclitaxel

9

6

 

 S-1 + oxaliplatin

8

5

 

 S-1 + docetaxel

8

2

 

 Capecitabine + oxaliplatin

2

3

 

 Capecitabine + cisplatin

1

2

 

 Capecitabine + trastuzumab

2

1

 

 S-1 + cisplatin + docetaxel

1

1

 
  1. Data are presented as number (percentage) of patients
  2. SMIHigh, high skeletal muscle mass; SMILow, low skeletal muscle mass; UGC, unresectable gastric cancer; SMI, skeletal muscle mass